English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Objectives: To evaluate the short-term effect of the botulinum toxin, type A (BTX-A) injection for the treatment of myofascial pain dysfunction syndrome.Materials u0026 Methods: Foueteen female patients suffering from myofascial pain dysfunction syndrome were included in this study. For all patients both the masseter and temporalis muscles were injected once with 20-30 Units of BTX-A respectively and followed up for three months. Follow up included clinical assessment of maximal inter-incisal opening, range of lateral movement and visual analogue scale for pain. Electromyography (EMG) images were ordered pre-operatively and at the end of 3 months’ period to quantify the changes in muscle activity. Results: Results of the present study showed resolution of pain in all patients upon completing the follow up period. Conclusion: Within the limits of this study BTX-A can be used effectively for the treatment of myofacial pain dysfunction syndrome.

THE USE OF BOTULINUM TOXIN INJECTION IN THE MANAGEMENT OF MYOFASCIAL PAIN DYSFUNCTION SYNDROME